Emergex Vaccines: Emergex Signs Contract of 1.79M with the UK Department of
LifeCare NewsABINGDON, United Kingdom, Nov. 17, 2023 (GLOBE NEWSWIRE) - Emergex Vaccines Holding Limited ('Emergex'), a clinical-stage biotechnology company addressing major global infectious diseases through the development of 100% synthetic T... Emergex Signs Contract of £1.79M with the UK Department of LifeCare News
Read full article »
Emergex is an England-based biotechnology company that develops and commercializes T-cell vaccines for the treatment of viral and bacterial infectious diseases.
Read more